Image of Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: results at week 144

LITERATURE

Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: results at week 144


Reports on the efficacy and safety of long-term entecavir treatment in chronic hepatitis B (CHB) predominantly genotype B or C are insufficient. This study presents the efficacy and safety of entecavir maleate in Chinese CHB patients. Patients were randomly assigned to receive 48-week treatment with either 0.5mg/day entecavir (group A) or 0.5mg/day entecavir maleate (group B), then all patients received treatment with 0.5mg/day entecavir maleate from week 49. Two hundred and seventy-five patients with CHB (HBeAg-positive: 218) were analyzed, predominantly (98.5%) with genotype B or C


Availability

REQJ538-04Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
-
Specific Detail Info
-
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous